374 related articles for article (PubMed ID: 27749412)
21. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment?
Teyateeti A; Teyateeti A; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 Sep; 45(9):672-678. PubMed ID: 32604105
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level ≤0.5 ng/mL.
Teyateeti A; Khan B; Teyateeti A; Chen B; Bridhikitti J; Pan T; Peng W; Macapinlac HA; Lu Y
Nucl Med Commun; 2020 Sep; 41(9):906-915. PubMed ID: 32796479
[TBL] [Abstract][Full Text] [Related]
23. 18F-Fluciclovine PET/CT in Therapeutic Decision Making for Prostate Cancer: A Large Single-Center Practice-Based Analysis.
Dreyfuss AD; Ahn GS; Barsky AR; Gillman JA; Vapiwala N; Pantel AR
Clin Nucl Med; 2021 Mar; 46(3):187-194. PubMed ID: 33315672
[TBL] [Abstract][Full Text] [Related]
24. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.
De Bari B; Mazzola R; Aiello D; Fersino S; Gregucci F; Alongi P; Nicodemo M; Cavalleri S; Salgarello M; Alongi F
Radiol Med; 2018 Sep; 123(9):719-725. PubMed ID: 29687208
[TBL] [Abstract][Full Text] [Related]
25. Effect of hormonal therapy on
Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
[TBL] [Abstract][Full Text] [Related]
26. 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.
England JR; Paluch J; Ballas LK; Jadvar H
Clin Nucl Med; 2019 Mar; 44(3):e128-e132. PubMed ID: 30589673
[TBL] [Abstract][Full Text] [Related]
27. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
28.
Rais-Bahrami S; Efstathiou JA; Turnbull CM; Camper SB; Kenwright A; Schuster DM; Scarsbrook AF
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):997-1006. PubMed ID: 34012062
[TBL] [Abstract][Full Text] [Related]
29. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
Marcus C; Butler P; Bagrodia A; Cole S; Subramaniam RM
AJR Am J Roentgenol; 2020 Aug; 215(2):267-276. PubMed ID: 32551903
[No Abstract] [Full Text] [Related]
30. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
31. PSMA-targeted Radiotracers versus
Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
[TBL] [Abstract][Full Text] [Related]
32. Small Lymph Node Metastasis Detected by 68Ga-Prostate-Specific Membrane Antigen But Not 18F-Fluciclovine PET/CT in Low-Prostate-Specific Antigen Biochemical Recurrence of Prostate Cancer.
Chaussé G; Abikhzer G; Probst S
Clin Nucl Med; 2018 Apr; 43(4):250-251. PubMed ID: 29465489
[TBL] [Abstract][Full Text] [Related]
33. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?
Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H
Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339
[TBL] [Abstract][Full Text] [Related]
34. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
35. Imaging of Prostate Cancer Using Fluciclovine.
Savir-Baruch B; Zanoni L; Schuster DM
PET Clin; 2017 Apr; 12(2):145-157. PubMed ID: 28267449
[TBL] [Abstract][Full Text] [Related]
36. Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences.
Hwang L; Paluch J; Jadvar H; England JR; Desai B; Ballas LK
Clin Nucl Med; 2020 Sep; 45(9):668-671. PubMed ID: 32520496
[TBL] [Abstract][Full Text] [Related]
37. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
38. Prospective Evaluation of
Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
[No Abstract] [Full Text] [Related]
39. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract][Full Text] [Related]
40. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
